Skip to content
DraconiticResearch
Search Sources API
190,860 studies31 sourcesUpdated 31 min ago
Peer-reviewedCC BYMolecular biology reports

GSTP1 promoter hypermethylation in prostate cancer detection: current evidence, clinical positioning, and translational gaps.

  • Jun-Lynn Joo1
  • Rebecca Shin-Yee Wong2,3,4
  • Bey Hing Goh5,6,7
  • Nancy Choon-Si Ng8,9
9 affiliations
  1. 1Department of Biomedical Sciences, Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Sunway City, Malaysia.
  2. 2Department of Medical Education, Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Sunway City, Malaysia.
  3. 3Faculty of Medicine, University of Cyberjaya, Cyberjaya, Malaysia.
  4. 4Centre for Learning and Teaching, University of Cyberjaya, Cyberjaya, Malaysia.
  5. 5School of Clinical and Health Sciences, Faculty of Health, University of Technology Sydney, NSW, 2007, Sydney, Australia. [email protected].
  6. 6Sunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University, Sunway City, Malaysia. [email protected].
  7. 7Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. [email protected].
  8. 8Department of Medical Education, Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Sunway City, Malaysia. [email protected].
  9. 9Graduate School of Medicine, KPJ Healthcare University, Nilai, Malaysia. [email protected].
Read full textPDFDOICite

Abstract

GSTP1 promoter hypermethylation is one of the most consistently documented molecular alterations in prostate cancer, with high prevalence in malignant tissue and a well-established relationship with transcriptional silencing. However, despite more than two decades of biological and diagnostic investigation, GSTP1-based testing has not acquired a clearly defined stand-alone role in contemporary prostate cancer detection. This narrative review examines why extensive biological evidence has not translated into routine clinical use and where, if anywhere, GSTP1 testing might provide meaningful value within current diagnostic pathways. Evidence from prostate tissue, urine and circulating cell-free DNA is considered alongside the effects of biospecimen selection, preanalytical handling, CpG target selection, assay design and interpretation thresholds. Tissue demonstrates the most reproducible signal and has achieved partial clinical translation through multiplex testing such as ConfirmMDx, whereas urinary and blood-based approaches remain investigational. Recent urinary findings, including in men with moderately elevated PSA, are promising but remain preliminary and have not established incremental value beyond contemporary risk assessment, biomarkers and multiparametric MRI. The translational priority is therefore not to demonstrate again that GSTP1 detects prostate cancer, but to determine whether a standardised assay provides reproducible, nonredundant and clinically actionable information at a defined decision point. Future development should prioritise clearly specified target populations, analytically validated assay configurations, clinically significant prostate cancer as the relevant endpoint, and prospective evaluation against contemporary diagnostic pathways.

Related

  1. Bisphenol A and prostate cancer: from population exposure to context-dependent mechanisms and translational implications
    Zhanhao Li, Hongliang Cao, Zihao Ye +5
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  2. Intracellular growth of Chlamydia trachomatis leads to global histone hypermethylation by impairing demethylation
    Chloé Charendoff, Félix Louchez, Yongzheng Wu +17
    eLifePeer-reviewedCC BYMolecular biology & gene regulationHAL
  3. Genetic integration reveals causal effects of chromatin accessibility on nucleosome positioning across diverse muscle cells
    Xiaoou Wang, Catherine C. Robertson, Arushi Varshney +11
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Molecular biology & gene regulationCrossref
  4. Promoter-targeted duplex RNAs activate TCF4 expression
    d. corey, B. Janowski, V. Tse +3
    bioRxivPreprintAll rights reservedFull textMolecular biology & gene regulationbioRxiv
  5. Molecular mechanisms of promoter silencing by transcriptional readthrough
    Gerry A. Shipman, Erika Walback, Andy García González +4
    Cell ReportsPeer-reviewedCC BY 4.0Molecular biology & gene regulationCrossref

Cite

BibTeXRIS
BibTeX
@article{joo2026gstp1,
  title = {{GSTP1 promoter hypermethylation in prostate cancer detection: current evidence, clinical positioning, and translational gaps.}},
  author = {Jun-Lynn Joo and Rebecca Shin-Yee Wong and Bey Hing Goh and Nancy Choon-Si Ng},
  journal = {Molecular biology reports},
  year = {2026},
  month = oct,
  doi = {10.1007/s11033-026-13011-2},
  url = {https://europepmc.org/article/MED/42905185},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - GSTP1 promoter hypermethylation in prostate cancer detection: current evidence, clinical positioning, and translational gaps.
AU  - Jun-Lynn Joo
AU  - Rebecca Shin-Yee Wong
AU  - Bey Hing Goh
AU  - Nancy Choon-Si Ng
PY  - 2026
DA  - 2026/10/21
JO  - Molecular biology reports
DO  - 10.1007/s11033-026-13011-2
UR  - https://europepmc.org/article/MED/42905185
AB  - GSTP1 promoter hypermethylation is one of the most consistently documented molecular alterations in prostate cancer, with high prevalence in malignant tissue and a well-established relationship with transcriptional silencing. However, despite more than two decades of biological and diagnostic investigation, GSTP1-based testing has not acquired a clearly defined stand-alone role in contemporary prostate cancer detection. This narrative review examines why extensive biological evidence has not translated into routine clinical use and where, if anywhere, GSTP1 testing might provide meaningful value within current diagnostic pathways. Evidence from prostate tissue, urine and circulating cell-free DNA is considered alongside the effects of biospecimen selection, preanalytical handling, CpG target selection, assay design and interpretation thresholds. Tissue demonstrates the most reproducible signal and has achieved partial clinical translation through multiplex testing such as ConfirmMDx, whereas urinary and blood-based approaches remain investigational. Recent urinary findings, including in men with moderately elevated PSA, are promising but remain preliminary and have not established incremental value beyond contemporary risk assessment, biomarkers and multiparametric MRI. The translational priority is therefore not to demonstrate again that GSTP1 detects prostate cancer, but to determine whether a standardised assay provides reproducible, nonredundant and clinically actionable information at a defined decision point. Future development should prioritise clearly specified target populations, analytically validated assay configurations, clinically significant prostate cancer as the relevant endpoint, and prospective evaluation against contemporary diagnostic pathways.
SN  - 0301-4851
SN  - 1573-4978
ER  -